{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.","id":"OG000","title":"Arm I- Cyproheptadine Hydrochloride"},{"description":"Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (\\> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.","id":"OG001","title":"Arm II Cyproheptadine HCl and PediaSure or Ensure"}],"populationDescription":"Outcome not assessed as the one subject that completed the protocol was too young to complete the PedsFAACT quality of life assessment.","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Quality of Life as Assessed by Peds-FAACT Questionnaire at Baseline and at Weeks 4 and 24","type":"SECONDARY"}